Literature DB >> 21672698

Risk profiles of Alzheimer disease.

Melanie Bilbul1, Hyman M Schipper.   

Abstract

Alzheimer disease (AD) is a dementing, neurodegenerative disorder that affects approximately 500,000 Canadians and its prevalence is expected to double over the next 30 years. Although several medications may temporarily augment cognitive abilities in AD, there presently exists no proven method to avoid the inevitable clinical deterioration in this devastating condition. The delineation of risk factors for the development of AD offers hope for the advent of effective prevention or interventions that might retard the onset of symptoms. In this article, we provide a comprehensive review of midlife risk factors implicated in the etiopathogenesis of sporadic AD. Although some risk factors are heritable and largely beyond our control, others are determined by lifestyle or environment and are potentially modifiable. In a companion paper, we introduce the concept of an Alzheimer Risk Assessment Clinic for ascertainment and mitigation of these and other putative dementia risk factors in middle-aged adults.

Entities:  

Mesh:

Year:  2011        PMID: 21672698     DOI: 10.1017/s0317167100012129

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  5 in total

1.  [Dementia and otorhinolaryngologic practice].

Authors:  S Eichhorn; G Hesse; A Laubert
Journal:  HNO       Date:  2014-09       Impact factor: 1.284

2.  Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Michael W Weiner; Dallas P Veitch; Jacqueline Hayes; Thomas Neylan; Jordan Grafman; Paul S Aisen; Ronald C Petersen; Clifford Jack; William Jagust; John Q Trojanowski; Leslie M Shaw; Andrew J Saykin; Robert C Green; Danielle Harvey; Arthur W Toga; Karl E Friedl; Anthony Pacifico; Yvette Sheline; Kristine Yaffe; Brian Mohlenoff
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

3.  Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer's disease dementia.

Authors:  Fabricio F de Oliveira; Elizabeth S Chen; Marilia C Smith; Paulo H Bertolucci
Journal:  Braz J Psychiatry       Date:  2017-01-12       Impact factor: 2.697

4.  Trichoderma reesei fungal degradation boosted the potentiality of date pit extract in fighting scopolamine-induced neurotoxicity in male rats.

Authors:  Samar R Saleh; Asmaa M Masry; Doaa A Ghareeb; Al-Sayeda A Newairy; Eman Sheta; Adham M Maher
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

5.  Anti-amyloid-β-mediated positron emission tomography imaging in Alzheimer's disease mouse brains.

Authors:  Daniel McLean; Michael J Cooke; Yuanfei Wang; David Green; Paul E Fraser; Peter St George-Hyslop; Molly S Shoichet
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.